DreaMed Diabetes has won CE Mark clearance for its Advisor Pro decision-support platform, designed to help healthcare professionals manage insulin therapy for their Type I diabetes patients.
The company’s cloud-based platform provides personalized insulin treatment plans by combining data from insulin pumps and continuous glucose monitors. Using machine learning techniques, the system analyzes all of the data it collects from connected devices to come up with an optimized insulin dosing treatment plan.
DreaMed, in partnership with Glooko, is conducting at 112-patient study of its Advisor Pro platform. The company plans to assess the technology’s ability to adjust blood glucose levels and prevent hypoglycemic events during a six-month period as compared to recommendations by diabetes experts. DreaMed said it’s slated to announce results from the trial by the end of this year.
“DreaMed Diabetes’ mission is to simplify treatment and improve patient experience with our intelligent, personalized diabetes decision support solutions for patients and healthcare providers,” CEO Eran Atlas said in prepared remarks.
“Our product is the only diabetes decision support solution that has received regulatory approval for optimizing insulin pump therapy using continuous glucose monitoring data. We therefore believe that it will be an important companion for doctors and patients alike in achieving optimal glycemic control and the data from our clinical feasibility studies support this conclusion. We are on track with our multi-center clinical trial for Advisor Pro, and are planning a soft launch for this revolutionary product in Europe in the summer of 2018.”
